ExxonMobil (XOM 0.26%) has raised its dividend for 43 consecutive years. That puts it on track to join the elite club of ...
In 2026, despite all the pressures they've faced from tariff uncertainty, elevated inflation, and higher interest rates, ...
Cricketnmore on MSN
'A Massive Boost For The Future Of Women Cricketersrsquo;: Tendulkar Hails ICC's Post-pregnancy Return Guidelines
International Cricket Council: Cricket legend Sachin Tendulkar has welcomed the International Cricket Council's newly ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...
Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...
Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...
Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...
Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...
Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results